{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-251073","form_type":"8-K","ticker":"APLS","cik":"0001492422","company_name":"Apellis Pharmaceuticals, Inc.","filed_at":"2023-10-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.231057+00:00","generated_at":"2026-06-10T03:55:54.921203+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Apellis reports preliminary SYFOVRE Q3 revenue ~$74M; total since launch ~$160M","bullets":["Approximately $74M in preliminary US net SYFOVRE revenue for Q3 2023; ~$160M total since March 2023 launch.","More than 100,000 vials (commercial+sample) distributed to date; ~37,000 commercial and 10,000 samples in Q3.","Permanent J-code effective Oct 1; >95% of Medicare payers now covering SYFOVRE.","GALE extension study shows up to 45% reduction in nonsubfoveal GA lesion growth at Months 24-30 vs projected sham.","Estimated retinal vasculitis rate remains rare at 0.01% per injection; 10 confirmed events, 2 suspected."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-251073","json":"https://secwatch.observer/filing/0001193125-23-251073.json","markdown":"https://secwatch.observer/filing/0001193125-23-251073.md","text":"https://secwatch.observer/filing/0001193125-23-251073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1492422/000119312523251073/0001193125-23-251073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1492422/000119312523251073/d555980d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T03:55:54.921203+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"78e99dff4798d97a0579ad00d0d6e6a3fb2553fa","claim":"Apellis Pharmaceuticals, Inc. reported third quarter of 2023 results: revenue approximately $74 million.","evidence_excerpt":"Apellis expects approximately $74 million in preliminary U.S. net product revenue for SYFOVRE in the third quarter and approximately $160 million in preliminary total U.S. net product revenue for SYFOVRE since launch in March 2023 through September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1492422/000119312523251073/0001193125-23-251073-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter of 2023"},{"label":"Revenue","value":"approximately $74 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}